Article Text

Download PDFPDF

Dapsone therapy for Henoch-Schönlein purpura: a case series
  1. H Iqbal,
  2. A Evans
  1. Queen Elizabeth Hospital, London, UK
  1. Correspondence to:
    Dr H Iqbal
    Department of Paediatrics, Queen Elizabeth Hospital, Stadium Road, Woolwich, London SE18 4QH, UK; humaitiscali.co.uk

Statistics from Altmetric.com

Henoch-Schönlein purpura (HSP), first recognised by Heberden in 1801, is a systemic, IgA mediated vasculitis of small vessels that is usually self-limiting but may progress to gastrointestinal bleeding, intussusception, and nephropathy. A third of patients will experience recurrences.1 Currently treatment is confined to rest, analgesia, and steroids for refractory abdominal pain,2 and immunosuppressants for complications, especially renal disease. Original reports, predominantly in adults, show that the symptoms of purpuric rash, abdominal pain, and arthritis in HSP respond to treatment with dapsone.3–5

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.